Corpus Intelligence IC Memo — BRYAN MEDICAL CENTER 2026-04-26 11:19 UTC
IC Memo — BRYAN MEDICAL CENTER
Investment Committee Memorandum | NE | 510 beds | Grade B | EBITDA uplift $62.1M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BRYAN MEDICAL CENTER

CCN 280003 | LANCASTER, NE | 510 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

BRYAN MEDICAL CENTER is a 510-bed suburban community hospital in LANCASTER, NE with $843.7M in net patient revenue and a 8.1% operating margin. The hospital serves a payer mix of 33.1% Medicare, 1.8% Medicaid, and 65.1% commercial.

Thesis: Platform Growth. Our ML models identify $62.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 8.1% to 15.4% (+736bps).

Net Revenue HCRIS$843.7M
Current EBITDA COMPUTED$68.2M
Operating Margin COMPUTED8.1%
Occupancy HCRIS74.7%
Revenue / Bed COMPUTED$1.7M
Net-to-Gross HCRIS33.1%
Distress Probability ML43.1%

2. Market Context & Competitive Position

98
NE Hospitals
-6.3%
State Median Margin
884
Comparable Hospitals

NE has 98 Medicare-certified hospitals with a median operating margin of -6.3%. The target's margin of 8.1% places it above the state median. Among 884 size-comparable peers (255-1020 beds), the median margin is -3.9%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (255-1020), prioritizing same-state peers. 884 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BRYAN MEDICAL CENTER (Target)NE510$843.7M8.1%
ST. LUKES HOSPITALPA633$8.94B87.9%
STANFORD HEALTH CARECA657$6.76B3.7%
UCSF MEDICAL CENTERCA834$5.44B-5.4%
UT MD ANDERSON CANCER CENTERTX721$4.90B-0.8%
UNIV OF MI HOSPITALS & HLTH CTMI951$4.62B-1.4%
MEMORIAL HOSPITAL FOR CANCER ANY514$4.34B-32.5%
CEDARS-SINAI MEDICAL CENTERCA908$3.92B-5.5%
MASSACHUSETTS GENERAL HOSPITALMA997$3.50B-44.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $62.1M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$17.7M+210bp18mo
Cost to Collect4.5%2.5%$16.9M+200bp12mo
Denial Rate Reduction12.0%6.5%$16.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$10.3M+122bp9mo
Clean Claim Rate88.0%96.0%$540K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$17.7M
Cost to Collect
$16.9M
Denial Rate Reduction
$16.7M
A/R Days Reduction
$10.3M
Clean Claim Rate
$540K
Total EBITDA Uplift$62.1M
Current EBITDA$68.2M
+ RCM Uplift+$62.1M
Pro Forma EBITDA$130.3M
Current Margin8.1%
Pro Forma Margin15.4%
WC Released (1x)$32.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$104.9M$1.07B10.21x59.1%
Base (11x exit)10.0x11.0x$104.9M$1.21B11.55x63.1%
Bull Case9.0x11.0x$94.4M$1.45B15.37x72.7%
Bull (12x exit)9.0x12.0x$94.4M$1.61B17.06x76.4%
Bear Case11.0x10.0x$115.4M$726.3M6.29x44.5%
Bear (11x exit)11.0x11.0x$115.4M$836.4M7.25x48.6%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 884 hospitals with 255-1020 beds
  • Same-state prioritization (n=4)
  • Comp margins: P25=-13.7% / P50=-3.9% / P75=4.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.